Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Jan;12(1):368-378.
doi: 10.1002/cam4.4849. Epub 2022 May 23.

Mesenchymal chondrosarcoma: An Australian multi-centre cohort study

Madeleine C Strach  1   2   3 , Peter S Grimison  1   2 , Angela Hong  1 , Richard Boyle  1   2 , Paul Stalley  1   2 , Rooshdiya Karim  2 , Elizabeth A Connolly  1 , Susie Bae  4   5 , Jayesh Desai  4   5 , Philip Crowe  6 , Nimit Singhal  7 , Vivek A Bhadri  1   2   3
Affiliations
Multicenter Study

Mesenchymal chondrosarcoma: An Australian multi-centre cohort study

Madeleine C Strach et al. Cancer Med. 2023 Jan.

Abstract

Background: Mesenchymal chondrosarcoma (MCS) is an ultra-rare sarcoma that follows a more aggressive course than conventional chondrosarcoma. This study evaluates prognostic factors, treatments (surgery, chemotherapy, and radiation), and outcomes in an Australian setting.

Methods: We collected demographics, clinicopathological variables, treatment characteristics, and survival status from patients with MCS registered on the national ACCORD sarcoma database. Outcomes include overall survival (OS) and progression-free survival (PFS).

Results: We identified 22 patients with MCS between 2001-2022. Median age was 28 (range 10-59) years, 19 (86%) had localised disease at diagnosis of whom 16 had surgery (84%), 11 received radiation (58%), and 10 chemotherapy (53%). Ten (52%) developed recurrence and/or metastases on follow-up and three patients with initial metastatic disease received surgery, radiation, and chemotherapy. At a median follow-up of 50.9 (range 0.4-210) months nine patients had died. The median OS was 104.1 months (95% CI 25.8-182.3). There was improved OS for patients with localised disease who had surgical resection of the primary (p = 0.003) and those with ECOG 0-1 compared to 2-3 (p = 0.023) on univariate analysis.

Conclusions: This study demonstrates contemporary Australian treatment patterns of MCS. The role of chemotherapy for localised disease remains uncertain. Understanding treatment patterns and outcomes help support treatment decisions and design of trials for novel therapeutic strategies.

Keywords: chemotherapy; mesenchymal chondrosarcoma; prognostic factors; treatment outcome.

PubMed Disclaimer

Conflict of interest statement

Madeleine C Strach has served on the advisory board for Specialised Therapeutics and received personal fees from Specialised Therapeutics. Angela Hong has received a consultancy fee from Bayer and Provectus. The other authors made no disclosures.

Figures

FIGURE 1
FIGURE 1
(A) This Kaplan–Meier curve illustrates the overall survival of Australian patients with mesenchymal chondrosarcoma. (B) This Kaplan–Meier curve illustrates the progression free survival of Australian patients with mesenchymal chondrosarcoma.
FIGURE 2
FIGURE 2
(A) This Kaplan–Meier curve illustrates the overall survival of Australian patients with mesenchymal chondrosarcoma by localised or metastatic disease status at diagnosis. (B) This Kaplan–Meier curve illustrates the overall survival in Australian patients with localised mesenchymal chondrosarcoma by ECOG group 0–1 compared to 2–3. (C) This Kaplan–Meier curve illustrates the overall survival in Australian patients with localised mesenchymal chondrosarcoma by surgical resection of the primary tumour.
See this image and copyright information in PMC

References

    1. Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am. 2009;91(5):1063‐1072. doi: 10.2106/jbjs.H.00416 - DOI - PubMed
    1. Lichtenstein L, Bernstein D. Unusual benign and malignant chondroid tumors of bone: a survey of some mesenchymal cartilage tumors and malignant chondroblastic tumors, including a few multicentric ones, as well as many atypical benign chondroblastomas and chondromyxoid fibromas. Cancer. 1959;12(6):1142‐1157. doi: 10.1002/1097-0142(195911/12)12:6<1142::aid-cncr2820120610>3.0.co;2-d - DOI - PubMed
    1. Amer KM, Munn M, Congiusta D, Abraham JA, Mallick AB. Survival and prognosis of chondrosarcoma subtypes: SEER database analysis. J Orthop Res. 2020;38(2):311‐319. doi: 10.1002/jor.24463 - DOI - PubMed
    1. Stacchiotti S, Frezza AM, Blay JY, et al. Ultra‐rare sarcomas: a consensus paper from the connective tissue oncology society community of experts on the incidence threshold and the list of entities. Cancer. 2021;127(16):2934‐2942. doi: 10.1002/cncr.33618 - DOI - PMC - PubMed
    1. Huvos AG, Rosen G, Dabska M, Marcove RC. Mesenchymal chondrosarcoma a clinicopathologic analysis of 35 patients with emphasis on treatment. Cancer. 1983;51(7):1230‐1237. doi: 10.1002/1097-0142(19830401)51:7<1230::aid-cncr2820510710>3.0.co;2-q - DOI - PubMed

Publication types